SCHEMBL13784137

SCHEMBL13784137

CCn1c(-c2ccc(-c3ccc(-c4nc5ccccc5nc4-c4ccccc4)cc3)cc2)nc2ccccc21

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.68
ALDH1A1 P00352 8/20 0.68
HPGD P15428 6/20 0.68
MAPT P10636 4/20 0.64
HTT P42858 3/20 0.64
NPSR1 Q6W5P4 3/20 0.64
SMN1; SMN2 Q16637 2/20 0.64
MEN1 O00255 1/20 0.64
NPC1 O15118 1/20 0.64
CYP1A2 P05177 1/20 0.64
CYP3A4 P08684 1/20 0.64
CYP2C9 P11712 1/20 0.64
CYP2C19 P33261 1/20 0.64
RAB9A P51151 1/20 0.64
GFER P55789 1/20 0.64
KMT2A Q03164 1/20 0.64
NLRP3 Q96P20 1/20 0.59
HSD17B10 Q99714 4/20 0.58
LMNA P02545 2/20 0.58
TSHR P16473 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5009162 0.89 KDM4E (0.77) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL13784132 0.89 KDM4E (0.66) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL13784139 0.87 TP53 (0.62) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL13784140 0.85 HSD17B10 (0.58) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL17915125 0.84 KDM4E (0.59) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL18999376 0.83 ALDH1A1 (0.64) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL19275978 0.83 KDM4E (0.77) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL21934004 0.83 KDM4E (0.54) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL17915153 0.83 KDM4E (0.60) KDM4EALDH1A1HPGDMAPTHTT
SCHEMBL24941657 0.82 KDM4E (0.71) KDM4EALDH1A1HPGDMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815412-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic appliance using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2014-08-26 US disclosed
US-8815412-B2 Quinoxaline derivative, and light-emitting element, light-emitting device, and electronic appliance using the quinoxaline derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2014-08-26 US disclosed
US-20090184633-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Appliance Using the Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-07-23 US disclosed
US-20090184633-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Appliance Using the Quinoxaline Derivative SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) 2009-07-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090184633-A1 Quinoxaline Derivative, and Light-Emitting Element, Light-Emitting Device, and Electronic Appliance Using the Quinoxaline Derivative H1-0, NQO2, GDI1 KDM4E 443/4885ALDH1A1 499/4885HPGD 955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.